Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase NA 1Phase 3 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 22Lymphoid 17Gastrointestinal 15CNS 11Other hematologic neoplasm 10Sarcoma 9Myeloid 9Head & Neck 9Breast 8Plasma cell 7Thoracic 4Endocrine 4Classical hematology 3Other solid neoplasm 2NET 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Gynecologic 1

Conditions

Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Neuroendocrine Tumors 1Advanced Lung Neuroendocrine Tumor 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × X-Rays × Endocrine × Clear all
NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT06959641 2026-05-22

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Northwestern University

Phase 2 Recruiting
33 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡